Arcus grabs US rights to a WuXi-built PD-1 as second wave of checkpoints builds by John Carroll — on August 17, 2017 09:37 AM EDTUpdated: 09:41 AM
Looking for an oncology reboot, Sanofi, Regeneron shoot for a fast and flashy FDA OK of a promising new PD-1 by John Carroll — on August 1, 2017 08:44 AM EDTUpdated: 10:14 AM
CheckMate-227: Bristol-Myers Squibb has a MYSTIC-sized problem on its hands by John Carroll — on July 28, 2017 08:36 AM EDTUpdated: 10:41 AM
PD-L1 checkpoint player Merck KGaA dives into next-gen work with F-star collaboration by John Carroll — on June 4, 2017 02:41 PM EDTUpdated: 03:01 PM
Pioneering Merck makes another breakthrough with PD-1 star Keytruda, grabbing first OK for a cancer biomarker by John Carroll — on May 23, 2017 05:25 PM EDTUpdated: May 24, 2017 08:52 AM
Incyte turns to Penn for a collaboration on next-gen cancer combos by Arsalan Arif — on February 23, 2017 10:14 AM EDTUpdated: 10:26 AM
In a stunner, Merck leaps ahead of rivals with combo Keytruda/chemo attack on lung cancer by John Carroll — on January 11, 2017 10:09 AM EDTUpdated: January 15, 2017 10:30 AM
Novartis promises a speedy CAR-T pitch, boasts about its slate of blockbusters-to-be by John Carroll — on October 25, 2016 06:33 AM EDTUpdated: October 26, 2016 09:59 PM
Bristol-Myers Squibb brings Opdivo to a joint immuno-oncology program with Nektar’s new T cell amplifier by John Carroll — on September 27, 2016 07:03 AM EDTUpdated: 07:07 AM
$42M in, Flagship startups merge into one immuno-microbiome platform with multiple targets by John Carroll — on July 12, 2016 03:11 AM EDTUpdated: 12:53 PM
Bristol-Myers’ nivolumab grabs its sixth breakthrough designation as new links to autoimmune diseases creep up by Arsalan Arif — on June 27, 2016 10:25 AM EDTUpdated: 11:24 PM
— on